Replimune (REPL) Operating Expenses (2017 - 2026)

Replimune has reported Operating Expenses for 10 years, with the latest figure at $73.3 million in Q1 2026.

• Quarterly Operating Expenses fell 7.55% year-over-year to $73.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $319.9 million (up 22.28% YoY) and the FY2026 annual result came in at $319.9 million, up 22.28% from the prior year.
• Operating Expenses climbed to $73.3 million in Q1 2026 per REPL's latest filing, from $71.9 million in the prior quarter.
• Over five years, Operating Expenses peaked at $90.4 million in Q2 2025 and troughed at $32.0 million in Q1 2022.
• A 5-year average of $60.3 million and a median of $58.8 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses jumped 65.67% in 2023, then slipped 7.7% in 2024.
• Over 5 years, Operating Expenses stood at $41.6 million in 2022, then jumped by 35.82% to $56.5 million in 2023, then gained by 16.77% to $66.0 million in 2024, then rose by 8.86% to $71.9 million in 2025, then grew by 2.05% to $73.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $73.3 million, $71.9 million, and $84.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.